IRIS UniCatt

Marchetti, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.400
NA - Nord America 2.819
EU - Europa 2.207
SA - Sud America 988
AF - Africa 109
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.533
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.693
SG - Singapore 1.931
BR - Brasile 824
SE - Svezia 589
CN - Cina 534
IT - Italia 516
IE - Irlanda 291
DE - Germania 210
IN - India 193
ID - Indonesia 176
VN - Vietnam 155
FR - Francia 121
GB - Regno Unito 98
RU - Federazione Russa 81
AR - Argentina 78
CZ - Repubblica Ceca 61
HK - Hong Kong 61
BD - Bangladesh 56
FI - Finlandia 55
MX - Messico 52
CA - Canada 51
IQ - Iraq 41
NL - Olanda 39
KR - Corea 33
TR - Turchia 32
JP - Giappone 28
PK - Pakistan 27
AT - Austria 26
CO - Colombia 23
PL - Polonia 23
UA - Ucraina 21
VE - Venezuela 21
ZA - Sudafrica 21
BE - Belgio 18
SA - Arabia Saudita 17
CI - Costa d'Avorio 15
ES - Italia 14
KE - Kenya 14
MA - Marocco 14
AZ - Azerbaigian 12
CH - Svizzera 12
EC - Ecuador 12
UZ - Uzbekistan 12
EG - Egitto 11
TN - Tunisia 11
ET - Etiopia 9
IR - Iran 9
NP - Nepal 9
PH - Filippine 9
IL - Israele 8
PY - Paraguay 8
UY - Uruguay 8
CL - Cile 6
KZ - Kazakistan 6
LT - Lituania 6
MY - Malesia 6
OM - Oman 6
AE - Emirati Arabi Uniti 5
JO - Giordania 5
PE - Perù 5
AU - Australia 4
CR - Costa Rica 4
DZ - Algeria 4
KG - Kirghizistan 4
KW - Kuwait 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
AO - Angola 3
BG - Bulgaria 3
HU - Ungheria 3
JM - Giamaica 3
LB - Libano 3
PA - Panama 3
PT - Portogallo 3
RO - Romania 3
TJ - Tagikistan 3
AL - Albania 2
BB - Barbados 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GY - Guiana 2
HN - Honduras 2
LV - Lettonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
Totale 9.519
Salva come PNG Salva come JPEG
Città #
Singapore 721
Ashburn 593
Dublin 287
Chandler 256
Jakarta 167
Rome 152
Milan 140
Beijing 136
Los Angeles 128
Boston 124
Princeton 116
New York 107
Hyderabad 103
Hefei 86
São Paulo 66
Munich 60
Frankfurt am Main 58
Hong Kong 58
Moscow 57
Washington 53
Ho Chi Minh City 52
Dallas 51
Chicago 47
Hanoi 39
Brno 38
San Mateo 37
Santa Clara 33
Buffalo 32
Seoul 31
The Dalles 27
Helsinki 26
Kent 25
Rio de Janeiro 25
Nuremberg 23
San Francisco 22
Seattle 22
Amsterdam 20
London 20
Marseille 20
Tokyo 20
Wilmington 19
Belo Horizonte 17
Naples 17
Pune 17
Stockholm 17
Toronto 17
Vienna 17
Warsaw 16
Abidjan 15
Ann Arbor 15
Brasília 15
Brooklyn 15
Brussels 15
Denver 15
Houston 15
Orem 15
Salt Lake City 15
Baghdad 14
Boardman 14
Bremen 14
Chennai 14
Dhaka 14
Paris 14
Turku 14
Campinas 13
Curitiba 13
Poplar 13
Atlanta 12
Bari 12
Bogotá 12
Düsseldorf 12
Johannesburg 12
Montreal 12
Nairobi 12
Shanghai 12
Brdo 11
Porto Alegre 11
Tashkent 11
Baku 10
Da Nang 10
Lappeenranta 10
Mexico City 10
Nanjing 10
Olomouc 10
Phoenix 10
Praia Grande 10
Salvador 10
Addis Ababa 9
Contagem 9
Manchester 9
Ankara 8
Augusta 8
Fairfield 8
Haiphong 8
Jacksonville 8
New Delhi 8
Portsmouth 8
São Gonçalo 8
Betim 7
Busto Arsizio 7
Totale 4.811
Salva come PNG Salva come JPEG
Nome #
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study 175
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments 134
Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel 130
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance 127
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach 121
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 110
Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment 110
Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients 107
BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation 107
BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score 106
Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis 106
Tolerability of bevacizumab in elderly ovarian cancer patients (Turbo study): A case-control study of a real-life experience 103
Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation 101
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study 100
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 96
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 94
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 94
Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850) 93
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. 93
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study 92
Fertility preservation in patients with BRCA mutations or Lynch syndrome 91
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study 89
Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis 86
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 86
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients 86
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment 83
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 82
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 81
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 81
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery 81
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 80
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer 80
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis 79
Pembrolizumab for advanced cervical cancer: safety and efficacy 78
Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact 77
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 76
Letrozole in the management of advanced ovarian cancer: An old drug as a new targeted therapy 76
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 75
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer 75
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study 73
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 72
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study 71
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 71
Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer 71
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status 70
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 70
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 69
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic 67
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 67
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer 66
Value of frozen section to tailor surgical staging in apparent early-stage epithelial ovarian cancer 66
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer 64
Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: Evaluation of feasibility and morbidity of different surgical techniques 62
Targeted drug delivery via folate receptors in recurrent ovarian cancer: A review 62
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies 60
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 59
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes 59
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 59
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 58
A commentary on the discrepancy between blood and tumour BRCA testing: An open question 58
Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report 58
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study 56
Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing 55
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 54
Fertility preservation in gynaecologic cancers 54
The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis 53
Ixabepilone for the treatment of endometrial cancer 53
Bartholin gland cancer 52
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 52
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors 51
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series 51
The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase 50
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 50
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations 49
Midtrimester isolated short femur and perinatal outcomes: A systematic review and meta-analysis 49
Radiation effects on male fertility 49
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors 49
Vulvodynia: Current opinion and treatment strategies 49
Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: Case report and literature review 48
Secondary cytoreductive surgery: Surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease 48
Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers 47
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 47
Nonabsorbable suture granuloma mimicking ovarian cancer recurrence at combined positron emission tomography/computed tomography evaluation: A case report 47
Bevacizumab in ovarian cancer: State of the art and unanswered questions 46
First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab 46
Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence 45
Olaparib, PARP1 inhibitor in ovarian cancer 45
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials 45
Immune check-point in endometrial cancer 45
Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis 45
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms 44
Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis 44
Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? 44
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling 44
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review 44
Skin metastases from endometrial cancer treated with electrochemotherapy: Case report and review of literature 44
PARP inhibition: A promising therapeutic target in ovarian cancer 43
Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis 43
Late aortic lymphocele and residual ovary syndrome after gynecological surgery 43
Imaging strategy in recurrent ovarian cancer: a practical review 43
Totale 7.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.734
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.734
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202157 0 0 0 0 0 0 27 4 2 9 15 0
2021/2022480 17 3 3 23 5 8 14 46 11 27 146 177
2022/20231.358 200 190 113 97 84 192 90 93 148 37 73 41
2023/20241.582 35 337 77 203 87 258 134 43 24 66 172 146
2024/20252.634 61 53 223 74 149 91 74 83 483 328 540 475
2025/20263.541 1.089 154 368 659 1.000 271 0 0 0 0 0 0
Totale 9.750